Volume | 28,481 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Pfizer Inc | PFE | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
38.65 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
494 | 28,481 | - | 36.17 - 54.93 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
08:11:47 | 1 | US$ 38.78 | USD |
Pfizer Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 218.76B | 5.65B | 5.61B | US$ 18.28B | US$ - | - | 7.40 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | US$ - | 4.28% | 05/11/23 | -181.54k | - |
Pfizer News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PFE Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 37.35 | 39.015 | 36.87 | 37.99 | 26,614,312 | 1.40 | 3.75% |
1 Month | 38.49 | 40.14 | 36.17 | 38.04 | 31,275,979 | 0.26 | 0.68% |
3 Months | 40.08 | 42.22 | 36.17 | 39.26 | 24,778,920 | -1.33 | -3.32% |
6 Months | 50.60 | 54.93 | 36.17 | 42.68 | 23,596,236 | -11.85 | -23.42% |
1 Year | 53.15 | 54.93 | 36.17 | 45.06 | 21,491,877 | -14.40 | -27.09% |
3 Years | 35.86 | 61.71 | 31.61 | 43.64 | 29,040,042 | 2.89 | 8.06% |
5 Years | 36.395 | 61.71 | 27.88 | 42.07 | 26,606,701 | 2.36 | 6.47% |
Pfizer Description
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor. |